Decentralized Trials & Research Alliance (DTRA) Announces Priorities and
Global Coalition Defines Initiatives to Accelerate the Adoption of
Decentralized Research and Improve Access for Participants
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- The Decentralized Trials &
Research Alliance (DTRA) today announced priorities and initial initiatives
designed to realize the full potential of decentralized research to improve
access and participation to make clinical trials more efficient, accessible,
and equitable. With more than 100 Member Organizations, DTRA is the leading
multi-stakeholder initiative focused on accelerating the global adoption of
DTRA members have defined four priority areas as a framework for new
1. To establish common nomenclature & definitions, archetypes and key
performance indicators around the practice of decentralized research.
2. To identify and promote best practices in decentralized research.
3. To prioritize education by building a knowledge repository and mechanisms
for information sharing.
4. To identify and remove barriers to decentralized research implementation,
establishing roadmaps to their resolution.
A full listing of the initiatives grouped by priority area is available here.
While each priority area has several associated initiatives, the following
have been prioritized in the immediate term:
o Create a comprehensive Decentralized Research Glossary that is easily
accessible to relevant stakeholders to establish common nomenclature and
definitions including defining archetypes of decentralized trials.
o Establish a collaborative Best Practices Repository with dynamic updates
of trusted resources for study teams to identify where existing pathways
exist for areas perceived as challenges as barriers.
o Compile a Data and Knowledge Repository with evidence of the impact of
decentralized research capable of supporting education, research, and
o Build a central library of global regulatory, legal, privacy, and culture
information that contains dynamic links to relevant regulatory sites to
assist in the removal of barriers to entry.
Over 100 DTRA Member Organizations are engaged in advancing policies, research
practices and technologies that will accelerate the global adoption of
patient-focused, inclusive, decentralized clinical trials and research.
Members include life-sciences research companies and patient advocacy
organizations; technology and service providers; and leading regulatory
authorities, such as the U.S. Food and Drug Administration.
Organizations interested in becoming alliance members can visit DTRA.org.
The Decentralized Trials & Research Alliance (DTRA) was convened to enable
collaboration of stakeholders to accelerate the adoption of patient-focused,
decentralized clinical trials and research within life sciences and healthcare
through education and research. It works to make research participation
accessible to everyone, enabled by the consistent, widespread adoption of
appropriate decentralized research methods.